Aligos Therapeutics announced that the company is delivering several oral and poster presentations at the 32nd Conference of the Asian Pacific Association for the Study of the Liver being held Feb 15 – 19 in Taipei, Taiwan at the Taipei International Convention Center. Data is being presented for ALG-055009, Aligos’ THR-beta agonist in clinical development for nonalcoholic steatohepatitis, as well as for several clinical and nonclinical stage investigational agents from its chronic hepatitis B portfolio. "At this year’s meeting, we look forward to sharing data demonstrating that ALG-055009, our thyroid hormone receptor-beta agonist in development for NASH, showed promising anti-lipid effects in subjects with hyperlipidemia," said Lawrence Blatt, Ph.D., MBA, CEO and Chairman of the Board at Aligos. "In addition, we have several presentations which demonstrate the potentially best-in-class antiviral activity of our CAM-E compound, ALG-000184, where notable reductions in HBsAg levels have been observed with higher and longer-term dosing in subjects with HBeAg-positive CHB."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ALGS:
- Aligos Therapeutics Presents Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver
- Aligos Therapeutics to Present at the SVB Securities Global Biopharma Conference
- Aligos announces portfolio reprioritization of NASH, extends cash runway
- Aligos Therapeutics Announces Strategic Reprioritization of NASH and COVID-19 Programs and Confirms Key Timelines and Extension of Cash Runway to Year-End 2024
- Cantor Fitzgerald biotech analyst to hold analyst/industry conference call